Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

• Published in: Advances in therapy 2022-05, Vol.39 (5), p.2065-2084
• Main Authors: Menzies-Gow, Andrew, Hoyte, Flavia L., Price, David B., Cohen, David, Barker, Peter, Kreindler, James, Jison, Maria, Brooks, Christopher L., Papeleu, Peggy, Katial, Rohit
• Format: Article
• Language: English
• Subjects: Adrenal Cortex Hormones - therapeutic use; Anti-Asthmatic Agents - therapeutic use; Antibodies, Monoclonal, Humanized; Asthma - drug therapy; Bronchodilator Agents - therapeutic use; Cardiology; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Endocrinology; Eosinophils; Humans; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Original Research; Pharmacology/Toxicology; Rheumatology
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-022-02098-1

Introduction Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite remission definition to characterize individual responses to benralizumab after 6 and 12 months. Methods In previous phase 3 studies, eligible patients were those with severe, uncontrolled asthma receiving medium- or high-dosage inhaled corticosteroids plus long-acting β 2 -agonists. This post hoc analysis included patients randomized to the approved benralizumab dose and not receiving oral corticosteroids (OCS) at baseline (SIROCCO/CALIMA) or OCS ≤ 12.5 mg per day (ZONDA). Individual remission components were zero exacerbations; zero OCS use; Asthma Control Questionnaire-6 (ACQ-6) score